talk about double talk.
The company is entertaining(meaning they haven't yet) entrance into a number of agreements with academic and private sector clinical research organizations that will facilitate initial studies(will facilitate, meaning they haven't started yet) to demonstrate scientific merit of CSTATI-1 and CS-S/BCC-1 that will predictably translate to human studies within the coming year, as clinical options for this patient population remain limited and the etiology of both aggressive squamous/basel cell carcinomas and Kaposi’s sarcoma is poor in immune compromised populations, comparative to other skin cancers. (really? you mean melanoma, the most aggressive skin cancer isn't?)
News 
Market Data 
Discover 
